Exploring the association between brain-derived neurotrophic factor levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients. Issue 1 (25th October 2022)

• Record Type: Journal Article
• Authors: Isayeva, Ulker; Manchia, Mirko; Collu, Roberto; Primavera, Diego; Deriu, Luca; Caboni, Edoardo; Iaselli, Novella; Sundas, Davide; Tusconi, Massimo; Pinna, Federica; Paribello, Pasquale; Scherma, Maria; Pisanu, Claudia; Meloni, Anna; Zai, Clement C.; Congiu, Donatella; Squassina, Alessio; Fratta, Walter; Fadda, Paola; Carpiniello, Bernardo
• Is Part Of: European psychiatry. Volume 65:Issue 1(2022)
• Publication Date: 2022-10-25
• Subjects: BDNF -- biomarkers -- complex disorders -- longitudinal trajectories -- schizophrenia; Psychiatry -- Periodicals; Mental illness -- Periodicals; Electronic journals; 616.89
• DOI: 10.1192/j.eurpsy.2022.2333
• Languages: English
• ISSNs: 0924-9338

Abstract

Abstract: Background and hypothesis: Schizophrenia spectrum disorders are among the most debilitating mental disorders and has complex pathophysiological underpinnings. There is growing evidence that brain-derived neurotrophic factor (BDNF) can play a role in its pathogenesis. The present study investigated the longitudinal variation of serum BDNF levels in a 24-month observational prospective cohort study of Sardinian psychotic patients and its relationship with psychopathological and cognitive changes. Furthermore, we examined whether genetic variation within the BDNF gene could moderate these relationships. Study design: Every 6 months, 105 patients were assessed for their BDNF serum levels, as well as for a series of psychopathological, cognitive, and social measures. We performed a targeted analysis of four tag single nucleotide polymorphisms within the BDNF gene that were selected and analyzed using polymerase chain reaction. Longitudinal data were analyzed using mixed-effects linear regression models. Study results: We observed a declining longitudinal trajectory of BDNF levels in psychotic patients in general, and in relation to the severity of depressive and negative symptoms. BDNF serum levels also declined in patients scoring lower in cognitive measures such as attention and speed of information processing and verbal fluency. The rs7934165 polymorphism moderated the significant association between verbal fluency and BDNF levels. Conclusions: These findings in patients from real-world settings suggest a plausible role of peripheral BDNF levels as a marker of illness burden in schizophrenia spectrum disorders.